Literature DB >> 15956705

Relaxin receptor expression in hepatic stellate cells and in cirrhotic rat liver tissue.

Robert G Bennett1, Katrina J Mahan, Martha J Gentry-Nielsen, Dean J Tuma.   

Abstract

Relaxin has antifibrotic effects on the hepatic stellate cells (HSCs) responsible for collagen deposition in cirrhosis. The expression of relaxin receptors LGR7 and LGR8 in HSCs and liver disease was examined. Activated and quiescent HSCs expressed LGR7, whereas only activated HSCs expressed LGR8. Relaxin, relaxin-3, or InsL3 treatment increased cAMP, suggesting activation of both receptors. LGR8 and LGR7 were present in cirrhotic rat liver, but were undetectable in normal liver. In conclusion, both LGR7 and LGR8 are expressed in activated HSCs and cirrhotic liver, suggesting that relaxin, InsL3, or relaxin-3 may be useful in the treatment of hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956705     DOI: 10.1196/annals.1282.027

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  4 in total

Review 1.  Advances in antifibrotic therapy.

Authors:  Zahra Ghiassi-Nejad; Scott L Friedman
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-12       Impact factor: 3.869

Review 2.  Anti-fibrotic actions of relaxin.

Authors:  C S Samuel; S G Royce; T D Hewitson; K M Denton; T E Cooney; R G Bennett
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

Review 3.  Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches.

Authors:  Areeba Ahmad; Riaz Ahmad
Journal:  Saudi J Gastroenterol       Date:  2012 May-Jun       Impact factor: 2.485

4.  Relaxin family peptide receptors Rxfp1 and Rxfp2: mapping of the mRNA and protein distribution in the reproductive tract of the male rat.

Authors:  Marcelo Filonzi; Laís C Cardoso; Maristela T Pimenta; Daniel B C Queiróz; Maria C W Avellar; Catarina S Porto; Maria F M Lazari
Journal:  Reprod Biol Endocrinol       Date:  2007-07-10       Impact factor: 5.211

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.